Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191762 · ClinicalTrials.gov registry record · Phase 3
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
A Phase 3 study of Chronic Kidney Disease and Hyperparathyroidism, sponsored by Kenneth R. Phelps, M.D..
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01191762 is a Phase 3 study of Chronic Kidney Disease and Hyperparathyroidism that has completed, run by Kenneth R. Phelps, M.D.. The registered enrollment target is 30 participants, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01191762, a Phase 3 study of Chronic Kidney Disease and Hyperparathyroidism, has completed, sponsored by Kenneth R. Phelps, M.D..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal \[PTH\]to maintain normocalcemia in chronic kidney disease. This study will examine the hypothesis with measures of phosphate homeostasis and calcium reabsorption. A double-blind trial of the intestinal phosphate binder sevelamer carbonate will be employed to examine whether reductions in phosphate influx alter distal nephron phosphate concentration and the \[PTH\] required for calcium reabsorption in the expected manner.
Conditions Studied
Interventions
- DRUG placebo
- DRUG sevelamer carbonate
Study Locations (1)
New York
- Stratton Veterans Affairs Medical Center - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191762
The ClinicalTrials.gov registry entry for NCT01191762 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The listed sponsor is Kenneth R. Phelps, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01191762 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01191762 about?
NCT01191762 is a clinical study titled "Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease". The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal \[PTH\]to maintain normocalcemia in chronic kidney disease. This study will examine the hypothesis with measures of phosphate homeostasi...
What is the current status of trial NCT01191762?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2010-04. Estimated completion is 2013-04.
What conditions does trial NCT01191762 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Hyperparathyroidism.
What interventions are being tested in trial NCT01191762?
The interventions under investigation include: placebo (DRUG), sevelamer carbonate (DRUG).
Who is sponsoring clinical trial NCT01191762?
This trial is sponsored by Kenneth R. Phelps, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01191762 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.